Candel Therapeutics (CADL) Common Equity: 2020-2023
Historic Common Equity for Candel Therapeutics (CADL) over the last 3 years, with Sep 2023 value amounting to $23.0 million.
- Candel Therapeutics' Common Equity fell 55.83% to $23.0 million in Q3 2023 from the same period last year, while for Sep 2023 it was $23.0 million, marking a year-over-year decrease of 55.83%. This contributed to the annual value of $47.7 million for FY2022, which is 25.61% down from last year.
- According to the latest figures from Q3 2023, Candel Therapeutics' Common Equity is $23.0 million, which was down 25.18% from $30.8 million recorded in Q2 2023.
- Candel Therapeutics' 5-year Common Equity high stood at $64.1 million for Q4 2021, and its period low was -$43.2 million during Q2 2021.
- In the last 3 years, Candel Therapeutics' Common Equity had a median value of $49.9 million in 2022 and averaged $40.1 million.
- In the last 5 years, Candel Therapeutics' Common Equity skyrocketed by 372.21% in 2021 and then plummeted by 55.83% in 2023.
- Candel Therapeutics' Common Equity (Quarterly) stood at -$23.6 million in 2020, then surged by 372.21% to $64.1 million in 2021, then declined by 25.61% to $47.7 million in 2022, then tumbled by 55.83% to $23.0 million in 2023.
- Its last three reported values are $23.0 million in Q3 2023, $30.8 million for Q2 2023, and $39.7 million during Q1 2023.